Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate
pharmacogenetics implementation in clinical practice by developing evidence-based …

Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of more drugs in clinical use
than any other foreign compound–metabolizing enzyme in humans. Recently, increasing …

Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone
immunosuppressive agents administered to solid organ transplant recipients to prevent and …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Introduction: Variability of drug response is an important consideration in clinical medicine. A
major determinant of drug response variability is hepatic cytochrome P450 oxidase …

Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ
transplantation. Finding the optimal balance between effective Tac concentrations and …